ACAndrew Jesse Connell

Andrew Jesse Connell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrew Jesse Connell has a total of 290 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Deletions in variable region 1 of the HIV envelope accelerate V3-glycan bNAb induction in SHIV-infected rhesus macaques

    by Michael P. Hogarty, Hui Li, Chengyan Zhao, Christian L. Martella, Ashwin N. Skelly, Rumi Habib, Andrew Jesse Connell, Frederic Bibollet-Ruche, Weimin Liu, John W. Carey, et al.

    Elicitation of broadly neutralizing antibodies (bNAbs) is a major goal of HIV-1 vaccine research. V3-glycan bNAbs were previously identified in a person living with HIV-1, CH848, and in two of six rhesus macaques (RMs) infected with a simian-HIV (SHIV) expressing the CH848 transmitted/founder envelope (Env) glycoprotein. In all cases, neutralization breadth developed after years of infection and only after the variable region 1 (V1) of Env had shortened in response to neutralizing antibodies. These observations suggested that V3-glycan bNAb elicitation might be accelerated if RMs were infected with SHIVs bearing CH848 Envs with truncated V1 loops. To test this hypothesis, we analyzed NAb responses in 10 RMs infected with SHIV.CH848 variants containing V1 deletions that mimicked those observed in natural infection. In three RMs, potent V3-glycan bNAbs developed within 1 y of infection, nearly three times faster than in wildtype CH848 infection. Longitudinal sequencing of B cell immunoglobulin genes revealed a single bNAb lineage in each RM that was primed as early as 8 to 12 wk postinfection and that largely recapitulated plasma breadth. A meta-analysis of the frequency of V3-glycan bNAb induction in RMs infected by SHIVs expressing CH848-derived Envs vs. 15 other primary HIV-1 Envs demonstrated a substantial enhancement in the CH848 group (5 of 16 vs. 2 of 109; P = 0.0003). We conclude that CH848 Envs have a propensity for inducing V3-glycan bNAbs and that truncations in their V1 loops accelerate precursor priming, findings that may guide HIV-1 vaccine design and inform current human vaccine trials.

  • Top Cited Papers
    Open Access

    Enhanced B cell priming induces broadly neutralizing HIV-1 apex antibodies

    by Lorie Marchitto, Kshitij Wagh, Ryan S. Roark, Severin Coleon, Hui Li, Ashwin N. Skelly, Michael P. Hogarty, Rumi Habib, Wenge Ding, Kasirajan Ayyanathan, et al.

    Efficient priming of B cell precursors is a rate-limiting step in the induction of V2 apex broadly neutralizing antibodies (bNAbs)1,2. Here, we describe a novel germline-targeted HIV-1 Env (CAP256.OPT4) that increases the efficiency of V2 apex bNAb precursor priming by 30-400 fold compared with wild-type HIV-1 Envs and induces - in >90% of macaques - neutralization breadth that includes N130-containing viruses. Using three different delivery platforms - persistently replicating simian human immunodeficiency viruses (SHIVs), protein nanoparticles, and mRNA - we show bNAb priming as early as 4 weeks post-infection or immunization, and neutralization breadth in plasma by 12 weeks. In 14 SHIV-infected macaques, neutralization breadth reached as high as 90% on a 21-virus panel with potency as great as 1:20,000 (50% inhibitory dilution, ID50). Monoclonal bNAbs isolated from these animals were similarly broad and potent, with cryo-EM structures representing three distinct lineages revealing canonical needle-like HCDR3 binding. Env-Ab coevolution and structural analyses identified five key residues and loop features under positive selection and temporally associated with neutralization breadth. Importantly, prime-boost immunogens designed to capture these features induced broad and potent neutralization of globally diverse viruses including those containing N130 glycan. Further, rhesus bNAbs were not restricted to IGHD3-15*01 heavy chain alleles. These results expand the utility of the rhesus model for HIV-1 vaccine design and provide a molecular blueprint for inducing V2 apex bNAbs in rhesus and humans.


  • Top Cited Papers
    Open Access

    Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design

    by Ashwin N. Skelly, Harry B. Gristick, Hui Li, Edem Gavor, Andrew J. Connell, Edward F. Kreider, Lorie Marchitto, Michael P. Hogarty, Maddy L. Newby, Joel D. Allen, et al.

    A major obstacle confronting HIV-1 vaccine and cure research is the lack of an outbred animal model for rapid and consistent induction of broadly neutralizing antibodies (bNAbs). We designed an epitope-focused simian-human immunodeficiency virus (SHIV.5MUT) that elicited broad and potent V3-glycan–targeted antibodies within a year of infection in 14 of 22 macaques compared with 0 of 14 control animals. SHIV.5MUT elicited bNAbs by a two-step mechanism, inducing an initial wave of V1-directed antibodies that selected for envelope (Env) glycoprotein variants with shortened, hypoglycosylated V1 loops, which in turn primed V3-glycan bNAb precursors. Rhesus bNAbs were immunogenetically and structurally diverse, closely resembling human V3-glycan bNAbs. Env-bNAb coevolution revealed a diverse repertoire of bNAb precursors and the Env variants that matured them, yielding a molecular blueprint for vaccine design.


  • Open Access

    mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model

    by Ashwin N. Skelly, Chengcheng Fan, Jennifer R. Keeffe, Arya B. Ökten, Edem Gavor, Maddy L. Newby, Joel D. Allen, Edward F. Kreider, Wenge Ding, Rebecca A. Osbaldeston, et al.

    The unyielding antigenic drift of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as the threat of future zoonotic sarbecovirus spillovers, has prompted the search for broadly neutralizing antibodies (bNAbs) to inform rational therapeutic and vaccine design. Here, we isolated and characterized 20 receptor binding domain (RBD)-directed bNAb lineages from a serially sampled SARS-CoV-2 patient who was infected and vaccinated during the early months of the pandemic. Thirteen of these targeted the highly conserved, cryptic class 1/4 or class 4 RBD epitopes and had long (18 to 26 amino acid) heavy chain complementarity determining region 3 loops that utilized the IGHD3-22 gene segment. Five bNAbs potently neutralized all 18 viruses in a panel containing SARS-CoV-2 variants up to the recently emerged XBB.1.5 and JN.1 strains as well as diverse sarbecoviruses from other clades. Structural analyses of the Ab401 and Ab568 bNAbs complexed with RBD and Spike trimer, respectively, revealed recognition features in common with other class 1/4 bNAbs. Prophylactic administration of Ab401 as a recombinant protein afforded robust protection against infectious challenge with either SARS-CoV-2_WA1 or a related bat sarbecovirus with zoonotic potential. A similar level of protection was achieved when the heavy and light chains of Ab401 were delivered as lipid nanoparticle-encapsulated mRNAs. These data expand the arsenal of SARS-CoV-2 bNAbs for clinical development and identify mRNA-based antibody delivery as a promising platform for both pandemic preparedness and protection of immunocompromised patients against emerging sarbecovirus variants.


  • Open Access

    Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodies

    by Ryan S. Roark, Rumi Habib, Jason Gorman, Hui Li, Andrew Jesse Connell, Mattia Bonsignori, Yicheng Guo, Michael P. Hogarty, Adam S. Olia, Kirsten J. Sowers, et al.

    Broadly neutralizing antibodies targeting the V2 apex of HIV-1 envelope are desired as vaccine design templates, but few have been described. Here, we report 11 lineages of V2 apex–neutralizing antibodies from simian-human immunodeficiency virus (SHIV)-infected rhesus macaques and determine cryo-EM structures for 9. A single V2 apex–neutralizing lineage accounted for cross-clade breadth in most macaques, and somatic hypermutation relative to breadth was generally low, exemplified by antibody V033-a.01 with <5% nucleotide mutation and 37% breadth (208-strain panel). Envelope complex structures revealed eight different antibody classes (one multi-donor) and the complete repertoire of all five possible recognition topologies, recapitulating canonical human modes of apex insertion and C-strand hydrogen bonding. Despite this diversity in recognition, all rhesus–V2 apex antibodies were derived from reading frame two of the DH3-15*01 gene. Collectively, these results define—in rhesus—the structural and genetic basis of HIV-1 V2 apex recognition and demonstrate unprecedented structural plasticity of a highly selected immunogenetic element.


  • Open Access

    Barriers to chimpanzee gene flow at the south‐east edge of their distribution

    by Noémie Bonnin, Alex K. Piel, Richard P. Brown, Yingying Li, Andrew Jesse Connell, Alexa N. Avitto, Jean P. Boubli, Adrienne Chitayat, Jasmin Giles, Madhurima S. Gundlapally, et al.

    Populations on the edge of a species' distribution may represent an important source of adaptive diversity, yet these populations tend to be more fragmented and are more likely to be geographically isolated. Lack of genetic exchanges between such populations, due to barriers to animal movement, can not only compromise adaptive potential but also lead to the fixation of deleterious alleles. The south‐eastern edge of chimpanzee distribution is particularly fragmented, and conflicting hypotheses have been proposed about population connectivity and viability. To address this uncertainty, we generated both mitochondrial and MiSeq‐based microsatellite genotypes for 290 individuals ranging across western Tanzania. While shared mitochondrial haplotypes confirmed historical gene flow, our microsatellite analyses revealed two distinct clusters, suggesting two populations currently isolated from one another. However, we found evidence of high levels of gene flow maintained within each of these clusters, one of which covers an 18,000 km2 ecosystem. Landscape genetic analyses confirmed the presence of barriers to gene flow with rivers and bare habitats highly restricting chimpanzee movement. Our study demonstrates how advances in sequencing technologies, combined with the development of landscape genetics approaches, can resolve ambiguities in the genetic history of critical populations and better inform conservation efforts of endangered species.


  • Open Access

    Zoonotic origin of the human malaria parasite Plasmodium malariae from African apes

    by Lindsey J. Plenderleith, Weimin Liu, Yingying Li, Dorothy E. Loy, Ewan Mollison, Jesse Connell, Ahidjo Ayouba, Amandine Esteban, Martine Peeters, Crickette M. Sanz, et al.

    The human parasite Plasmodium malariae has relatives infecting African apes (Plasmodium rodhaini) and New World monkeys (Plasmodium brasilianum), but its origins remain unknown. Using a novel approach to characterise P. malariae-related sequences in wild and captive African apes, we found that this group comprises three distinct lineages, one of which represents a previously unknown, highly divergent species infecting chimpanzees, bonobos and gorillas across central Africa. A second ape-derived lineage is much more closely related to the third, human-infective lineage P. malariae, but exhibits little evidence of genetic exchange with it, and so likely represents a separate species. Moreover, the levels and nature of genetic polymorphisms in P. malariae indicate that it resulted from the zoonotic transmission of an African ape parasite, reminiscent of the origin of P. falciparum. In contrast, P. brasilianum falls within the radiation of human P. malariae, and thus reflects a recent anthroponosis.


  • Open Access

    CD4 receptor diversity represents an ancient protection mechanism against primate lentiviruses

    by Ronnie M. Russell, Frederic Bibollet-Ruche, Weimin Liu, Scott Sherrill-Mix, Yingying Li, Jesse Connell, Dorothy E. Loy, Stephanie Trimboli, Andrew G. Smith, Alexa N. Avitto, et al.

    Significance: The CD4 protein of primates has undergone rapid diversification, but the reasons for this remain unknown. Here we show that within-species diversity of the HIV/simian immunodeficiency virus (SIV) envelope (Env) binding (D1) domain is common among African primate species, and that these polymorphisms can inhibit SIV Env-mediated cell entry. Amino acid replacements in the D1 domain changed putative Env contact residues as well as potential N -linked glycosylation sites in many species, with evidence for parallel evolution and trans-specific polymorphism. These data suggest that the primate CD4 receptor is under long-term balancing selection and that this diversification has been the result of a coevolutionary arms race between primate lentiviruses and their hosts.


  • Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption

    by Marcos V. P. Gondim, Scott Sherrill-Mix, Frederic Bibollet-Ruche, Ronnie M. Russell, Stephanie Trimboli, Andrew G. Smith, Yingying Li, Weimin Liu, Alexa N. Avitto, Julia C. DeVoto, et al.

    Interferon-mediated pressures vary throughout HIV-1 infection but are the highest during viral rebound after treatment interruption.


  • Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth

    by Ryan S. Roark, Hui Li, Wilton B. Williams, Hema Chug, Rosemarie D. Mason, Jason Gorman, Shuyi Wang, Fang-Hua Lee, Juliette Rando, Mattia Bonsignori, et al.

    Convergent HIV evolution across species: Human immunodeficiency virus (HIV) has a highly diverse envelope protein that it uses to target human cells, and the complexity of the viral envelope has stymied vaccine development. Roark et al. report that the immediate and short-term evolutionary potential of the HIV envelope is constrained because of a number of essential functions, including antibody escape. Consequently, when introduced into humans as HIV or into rhesus macaque monkeys as chimeric simian-human immunodeficiency virus, homologous envelope glycoproteins appear to exhibit conserved patterns of sequence evolution, in some cases eliciting broadly neutralizing antibodies in both hosts. Conserved patterns of envelope variation and homologous B cell responses in humans and monkeys represent examples of convergent evolution that may serve to guide HIV vaccine development. Science , this issue p. eabd2638